DrugBiological
Cemiplimab clinical trials
Also written REGN2810 and Libtayo.
- studies test it
- 151
- open now
- 73
- in phase 3
- 13
- first study started
- 2010
Keep track of what changes. Save the cemiplimab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
149 studies that test it; most in 2026 (31); 2 more planned to start later
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2015 | 1 |
| 2016 | 3 |
| 2017 | 6 |
| 2018 | 12 |
| 2019 | 7 |
| 2020 | 13 |
| 2021 | 12 |
| 2022 | 10 |
| 2023 | 14 |
| 2024 | 14 |
| 2025 | 25 |
| 2026 | 31 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 53
- Phase 2
- 111
- Phase 3
- 13
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
- Melanoma
- 13
Who runs them
Industry 54 · Other 97
Regeneron Pharmaceuticals (35) · M.D. Anderson Cancer Center (12) · National Cancer Institute (NCI) (6) · H. Lee Moffitt Cancer Center and Research Institute (5) · Memorial Sloan Kettering Cancer Center (4) · Sanofi (4) · Mayo Clinic (3) · University of Southern California (2)
Often tested with
Tested in the same studies.
Fianlimab (16) · Pembrolizumab (9) · Paclitaxel (6) · Nivolumab (5) · Atezolizumab (4) · Carboplatin (4) · Cetuximab (4) · Albumin-Bound Paclitaxel (3)
Studies
Open first, then newest update. How each study uses cemiplimab is read from its arms, and is right about nine times in ten.
Testing it · 151
- A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaRecruitingPhase 2Regeneron PharmaceuticalsNCT06769698Written as Cemiplimab
- Laser Interstitial Thermal Therapy (LiTT) With Cemiplimab or Other Chemotherapy in Recurrent GlioblastomasNot yet recruitingPhase 2Washington University School of MedicineNCT07620548Written as Cemiplimab
- Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell CarcinomaNot yet recruitingPhase 2Washington University School of MedicineNCT07715734Written as Cemiplimab
- Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid CancerNot yet recruitingPhase 2M.D. Anderson Cancer CenterNCT07470489Written as Cemiplimab
- A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior ChemotherapyRecruitingPhase 3ETOP IBCSG Partners FoundationNCT06931717Written as Cemiplimab
- Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck CancerRecruitingPhase 2National Cancer Institute (NCI)NCT07195734Written as Cemiplimab
- Cemiplimab and Quad Shot Radiation for Cutaneous Squamous Cell Carcinoma in the Head and NeckRecruitingEarly Phase 1Vanderbilt-Ingram Cancer CenterNCT07869823Written as Cemiplimab
- Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)RecruitingPhase 2/3SWOG Cancer Research NetworkNCT06616584Written as Cemiplimab
- Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell CarcinomaNot yet recruitingPhase 2Melanoma and Skin Cancer Trials LimitedNCT06418724Written as Cemiplimab
- A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With MelanomaRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT06594991Written as Cemiplimab
- A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)RecruitingPhase 3Regeneron PharmaceuticalsNCT06246916Written as cemiplimab
- Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node or Other High Risk FeaturesRecruitingPhase 2Georgetown UniversityNCT06449313Written as Cemiplimab-Rwlc
- RADICAL-IO: thRee Cycles of immunotherApy Without raDical Therapy In mediCALly InOperable Stage I Non-small Cell Lung CancerNot yet recruitingPhase 2The Netherlands Cancer InstituteNCT07808138Written as Cemiplimab 350 mg IV
- XL092 and Cemiplimab in BRAF WT Thyroid CancerRecruitingPhase 1UNC Lineberger Comprehensive Cancer CenterNCT06902376Written as Cemiplimab
- Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell CarcinomaRecruitingPhase 2National Cancer Institute (NCI)NCT07281417Written as Cemiplimab
- Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced LeiomyosarcomaRecruitingPhase 2Gabriel TinocoNCT06528769Written as Cemiplimab
- Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung CancerRecruitingPhase 2Mayo ClinicNCT06918132Written as Cemiplimab
- REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell CarcinomaRecruitingPhase 1/2Regeneron PharmaceuticalsNCT07594106Written as REGN15505+Cemiplimab
- Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) CancersRecruitingPhase 1/2Regeneron PharmaceuticalsNCT03564340Written as Cemiplimab
- Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/ImmunotherapyRecruitingPhase 2Wake Forest University Health SciencesNCT04253964Written as Cemiplimab-Rwlc
See all 151 studies that test cemiplimab →
Given in every arm · 50 — cemiplimab is usual care beside what is tested
- TOP 2301: Neoadjuvant Chemo for NSCLCRecruitingPhase 2Duke UniversityNCT06385262Written as Cemiplimab
- Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck CancerRecruitingPhase 2National Cancer Institute (NCI)NCT06980038Written as Cemiplimab
- International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From IsatuximabEnrolling by invitationPhase 2SanofiNCT05669989Written as Cemiplimab (SAR439684)
- Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain MetsRecruitingPhase 3InSightecNCT05317858Written as Cemiplimab
- A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid TumorsRecruitingPhase 1/2Biohaven Therapeutics Ltd.NCT06384807Written as Cemiplimab
- Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian CancerRecruitingPhase 2Regeneron PharmaceuticalsNCT06787612Written as Cemiplimab
- A Study Comparing Cemiplimab-based Treatments for Adult Participants With Locally Advanced Basal Cell Skin Cancer (laBCC)Not yet recruitingPhase 2Regeneron PharmaceuticalsNCT07808515Written as Cemiplimab
- A Study of Cemiplimab and Fianlimab in People With Nasopharyngeal CarcinomaNot yet recruitingPhase 1Memorial Sloan Kettering Cancer CenterNCT07650266Written as Cemiplimab
- Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With Pleural MesotheliomaRecruitingPhase 2Intergroupe Francophone de Cancerologie ThoraciqueNCT07234058Written as Cemiplimab
- Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung CancerRecruitingPhase 1BioNTech SENCT05142189Written as Cemiplimab
- A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck CancerRecruitingPhase 1Memorial Sloan Kettering Cancer CenterNCT04722523Written as Cemiplimab
- Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal CancerRecruitingPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT07281768Written as Cemiplimab
- A Phase 1 Study of BHV-1530 in Advanced Solid TumorsRecruitingPhase 1Biohaven Therapeutics Ltd.NCT06874335Written as Cemiplimab
- A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care TreatmentsRecruitingPhase 1Regeneron PharmaceuticalsNCT05137054Written as Cemiplimab
- Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal CancerRecruitingPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT06205836Written as Cemiplimab
- Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLCRecruitingPhase 2Weill Medical College of Cornell UniversityNCT06623656Written as Cemiplimab
- Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%RecruitingPhase 2Swiss Cancer InstituteNCT07020065Written as Cemiplimab
- Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung CancerRecruitingPhase 2Montefiore Medical CenterNCT06865339Written as Cemiplimab
- Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid TumorsRecruitingPhase 1Ankyra Therapeutics, IncNCT06171750Written as Cemiplimab
- Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell CarcinomaRecruitingPhase 2University of OklahomaNCT07223541Written as Cemiplimab 350 MG Intravenous Solution
Showing 20 of 50.
As the comparator · 1 — what is tested is compared with cemiplimab
Codes
What other systems call cemiplimab · ClinicalTrials.gg INT000975
- MeSH (NLM) C000627974cemiplimabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 6QVL057INTCEMIPLIMABConfirmed FDA, NLM
- RxNorm 2058826One source FDA
- NCI Thesaurus C121540CemiplimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000627974 | cemiplimab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 6QVL057INT | CEMIPLIMAB | Confirmed FDA, NLM |
| RxNorm | 2058826 | — | One source FDA |
| NCI Thesaurus | C121540 | Cemiplimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.